BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16982296)

  • 1. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
    Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
    Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
    Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
    Machado AR; Arns Cda C; Follador W; Guerra A
    Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstein R
    Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
    [No Abstract]   [Full Text] [Related]  

  • 7. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
    Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
    Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
    Alaniz C; Pogue JM
    Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.
    Powers JH; Ross DB; Lin D; Soreth J
    Chest; 2004 Jul; 126(1):314-5; author reply 315-6. PubMed ID: 15249482
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Lyles A
    Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
    [No Abstract]   [Full Text] [Related]  

  • 13. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
    Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
    Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
    Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
    Collins CD; Schwemm AK
    Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
    Chavanet P
    Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
    Lin PC; Wang BC; Kim R; Magyar A; Lai CC; Yang YW; Huang YC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):46-51. PubMed ID: 26454421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study.
    Wan Y; Li Q; Chen Y; Haider S; Liu S; Gao X
    J Med Econ; 2016; 19(1):53-62. PubMed ID: 26490296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.